Kymera Therapeutics KYMR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's operating cash flow?
- Kymera Therapeutics (KYMR) reported operating cash flow of -$88.84M in Q1 2026.
- How has Kymera Therapeutics's operating cash flow changed year-over-year?
- Kymera Therapeutics's operating cash flow decreased by 12.2% year-over-year, from -$79.15M to -$88.84M.
- What is the long-term trend for Kymera Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Kymera Therapeutics's operating cash flow has grown at a 15.9% compound annual growth rate (CAGR), from -$128.95M to -$232.89M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.